# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with ...
World's Largest Psychedelics Conference Boasts 12K Attendees
Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ: REUN) reported fiscal results for the fourth quarter and ye...
Specialty biotech company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed a pre-submission facility correspondence in advance...
Potentially, a significant business casualty has befallen the psychedelic sector.
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered
Closely following the announcement of what's to become of the new regulations for telehealth, including ketamine therapy, s...
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization ...
Ketamine therapy provider Field Trip Health & Wellness Ltd. (OTCQB: FTHWF) shared its Q3 2023 results for three and nine mo...